Feb 2017

Axxam and Fulcrum Therapeutics Initiate a Partnership for the Provision of Drug Discovery Services for Genetic Diseases

February 1st, 2017 - Axxam SpA (Milan/Italy), an innovative Partner Research Organization (iPRO) and leading provider of discovery services has entered into an agreement with Fulcrum Therapeutics Inc., a U.S.-based biotech founded in July 2016 by Third Rock Ventures. Fulcrum Therapeutics is focused on discovering and developing small molecule therapies to unlock gene control and the collaboration will utilize Axxam’s world-leading screening platform to identify novel targets for regulating gene expression. The programme will initially focus on genetic diseases where no effective treatment options currently exist.

Open PDF Document

Jan 2017

Axxam SpA is a member of the PHAGO Consortium

Milan (Italy) - January, 11th 2017 - Axxam is proud to announce its participation to the PHAGO project, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD). Axxam will contribute its expertise for the development of high-throughput screening systems suitable for the discovery of modulators of the TREM2/CD33 pathway. For more information please open the Press Release from the Phago Consortium.

Open PDF document